In Brief: Visx
This article was originally published in The Gray Sheet
Visx: Firm gains FDA approval of a premarket approval application supplement for use of its Star excimer laser in correcting myopic astigmatism of -0.75 to -0.4 diopters in patients with myopia of between -1 and -6 diopters. In January, the agency's Ophthalmic Devices Panel recommended that FDA approve the indication. The Santa Clara, California-based firm received an approvable letter in February ("The Gray Sheet" Feb. 17, In Brief). Per the panel's recommendation, the age limit for the new indication is raised from 18 and over to those 21 and over...
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.